Bendamustine Dry-Powder Formulation for Stable Reconstitution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lyophilized formulations of bendamustine are unstable, difficult to reconstitute, and prone to degradation due to high reactivity in aqueous solutions, leading to impurity formation and reduced potency, necessitating rapid reconstitution and storage challenges.
Innovation Solution
Development of stable dry-powder formulations and solid dispersions of bendamustine using non-aqueous solvents and pharmaceutically acceptable excipients, such as mannitol, which minimize aqueous exposure and enhance thermodynamic stability, facilitating easier reconstitution and improved impurity profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If bendamustine is formulated as a lyophilized powder for injection, then it can be stored for extended periods, but it requires difficult and time-consuming reconstitution by skilled hospital personnel
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by using bendamustine free base instead of hydrochloride salt, and by employing a non-aqueous solvent system (ethanol/water) that enables direct reconstitution without complex procedures. This parameter change resolves the contradiction by maintaining storage stability while dramatically simplifying reconstitution to a simple addition of sterile water.
Solution Approach 2:
The patent extracts the problematic hydrochloride salt component and the complex lyophilization process, replacing them with a free base formulation that can be directly reconstituted. This extraction of the problematic elements resolves the contradiction between storage stability and ease of reconstitution.
2Stability of the object's composition
If bendamustine is supplied as a lyophilized product requiring reconstitution, then it maintains stability during storage, but it is subject to degradation by hydrolysis once in aqueous solution
Solution Approach 1:
The patent minimizes the time that bendamustine spends in aqueous solution by enabling direct reconstitution of the free base form, which rapidly dissolves and can be immediately administered. This rushing through the aqueous phase resolves the hydrolysis degradation issue while maintaining storage stability.
Solution Approach 2:
The patent changes the chemical form from hydrochloride salt to free base, and uses a non-aqueous ethanol/water solvent system that prevents hydrolysis during storage. This parameter change resolves the contradiction by eliminating the hydrolysis pathway while maintaining stability.
3Stability of the object's composition
If current lyophilized formulations are used, then bendamustine can be stored stably, but degradation products occur during manufacturing and lyophilization processes
Solution Approach 1:
The patent extracts and eliminates the hydrochloride salt formation step and the complex lyophilization process that generate degradation products. By using a simple free base formulation with non-aqueous solvent, the patent removes the sources of harmful degradation products while maintaining storage stability.
Solution Approach 2:
The patent converts the potential harm of using non-aqueous solvents (which could leave residues) into a benefit by selecting ethanol, which is pharmaceutically acceptable and easily removed, thereby eliminating degradation products associated with traditional lyophilization while maintaining stability.
4Ease of operation
If bendamustine is reconstituted with Sterile Water for Injection, then it can be administered intravenously, but the reconstituted product must be administered within a limited time frame due to instability
Solution Approach 1:
The patent changes the chemical form to free base and uses a non-aqueous formulation that, when reconstituted, provides enhanced stability in the reconstituted solution. This parameter change resolves the contradiction by extending the administration time window while maintaining ease of reconstitution.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dry-powder formulations exhibit increased stability, reduced impurities, and improved reconstitution efficiency, allowing for longer storage and administration flexibility while maintaining therapeutic effectiveness.
Implementation Method 1
Once in aqueous solution, nitrogen mustards are subject to degradation by hydrolysis
Data Source
AI summary
Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.